Jazz Pharmaceuticals plc (NASDAQ:JAZZ) Shares Sold by Rhumbline Advisers

Rhumbline Advisers cut its stake in Jazz Pharmaceuticals plc (NASDAQ:JAZZ - Free Report) by 8.4% during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 169,400 shares of the specialty pharmaceutical company's stock after selling 15,597 shares during the quarter. Rhumbline Advisers owned about 0.27% of Jazz Pharmaceuticals worth $18,080,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also made changes to their positions in JAZZ. Capital World Investors purchased a new position in Jazz Pharmaceuticals during the 1st quarter worth $171,943,000. Swedbank AB purchased a new position in Jazz Pharmaceuticals during the 2nd quarter worth $106,936,000. Vestal Point Capital LP purchased a new position in Jazz Pharmaceuticals during the 4th quarter worth $89,175,000. Armistice Capital LLC grew its stake in Jazz Pharmaceuticals by 108.4% during the 4th quarter. Armistice Capital LLC now owns 651,626 shares of the specialty pharmaceutical company's stock worth $80,150,000 after buying an additional 338,882 shares during the last quarter. Finally, Perpetual Ltd grew its stake in Jazz Pharmaceuticals by 54.0% during the 1st quarter. Perpetual Ltd now owns 475,018 shares of the specialty pharmaceutical company's stock worth $57,202,000 after buying an additional 166,543 shares during the last quarter. 89.14% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

Several brokerages recently weighed in on JAZZ. Cantor Fitzgerald restated an "overweight" rating and set a $140.00 target price on shares of Jazz Pharmaceuticals in a research note on Monday. Wells Fargo & Company lowered their price target on Jazz Pharmaceuticals from $140.00 to $120.00 and set an "equal weight" rating for the company in a research report on Thursday, August 1st. Needham & Company LLC lowered their price target on Jazz Pharmaceuticals from $208.00 to $205.00 and set a "buy" rating for the company in a research report on Thursday, August 1st. Robert W. Baird lowered their price target on Jazz Pharmaceuticals from $160.00 to $154.00 and set an "outperform" rating for the company in a research report on Thursday, August 1st. Finally, StockNews.com raised Jazz Pharmaceuticals from a "buy" rating to a "strong-buy" rating in a research report on Thursday, August 1st. Four analysts have rated the stock with a hold rating, eleven have assigned a buy rating and one has issued a strong buy rating to the company's stock. Based on data from MarketBeat, the company currently has a consensus rating of "Moderate Buy" and an average price target of $173.07.

Jazz Pharmaceuticals Stock Performance

Shares of JAZZ stock traded down $0.68 on Monday, hitting $106.46. The company had a trading volume of 510,337 shares, compared to its average volume of 691,470. The firm has a market cap of $6.57 billion, a P/E ratio of 21.95, a price-to-earnings-growth ratio of 1.34 and a beta of 0.57. The company has a 50-day moving average price of $109.75 and a 200-day moving average price of $112.12. The company has a quick ratio of 2.02, a current ratio of 2.37 and a debt-to-equity ratio of 1.36. Jazz Pharmaceuticals plc has a twelve month low of $99.06 and a twelve month high of $137.57.

Jazz Pharmaceuticals Profile

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.